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Early stage detection of cancer is the key to provide a
better outcome for therapeutic intervention. Proteomic
technologies hold recently great promise in the search
of new clinical biomarkers for the early detection and
diagnosis of cancer or for the development of new
vaccines.
In this perspective, we will present our recent work in
improving early diagnosis of ovarian cancer (OC) by
combining MS analysis of serum peptidome with data
collected over a period of 7 years from the United King-
dom Collaborative Trial of Ovarian Cancer Screening.
Using 295 patients with OC, 290 with benign neoplasm,
and 2236 postmenopausal healthy controls, our results
showed that OC could be accurately predicted up to 15
months before its clinical diagnosis, based a combina-
tion of two MS peaks with CA125 clinical test. An over-
all sensitivity of 94.8% (96.6% specificity) was obtained
when comparing malignancies versus healthy postmeno-
pausal controls. High classification accuracies were also
obtained for early-stage cancers (93.5% sensitivity). MS
discriminatory peaks were identified as connective tis-
sue-activating peptide III (CTAPIII) and platelet factor 4
(PF4), platelet-derived chemokines, suggesting a link
between platelet function and tumour development.
Those markers might be promising for clinical use in
cancer early detection and treatment.
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